02591 銀諾醫藥－Ｂ
INNOGEN-B
INNOGEN-B
| Listing Date | 2025/08/15 |
| Listing Price | 18.680 |
Subscription Result
- Subscription Rate5,341.66x
- Guarantee One Lot Size--
- One Lot Success Rate0.5%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Guangzhou Innogen Pharmaceutical Group was founded in 2014, it has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
--
The Group’s pipeline currently comprises its Core Product, Efsubaglutide Alfa, which is being developed for the treatment of obesity and being overweight, and metabolic dysfunction-associated steatohepatitis (MASH), as well as five candidates in the pre-clinical stage.
--
The Group successfully obtained regulatory approval in January 2025 for Efsubaglutide Alfa for the treatment of type 2 diabetes (T2D) in China and commercialized in China in February 2025. The Group is the first company in Asia and third globally to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist.
--
The Group’s key customers include hospitals as well as online and retail channels, including online and offline pharmacies, internet hospitals, online clinics, and top e-commerce platforms.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 36.56M H shares |
| No. of International Offer Shares | 32.90M H shares |
| No. of HK Offer Shares | 3.66M H shares |
| Offer Price | $18.68 |
| Stock Code | 2591 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited, China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, Deutsche Bank AG, Hong Kong Branch, Macquarie Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, ABCI Securities Company Limited, BOCOM International Securities Limited, CMB International Capital Limited, Fosun International Securities Limited, Futu Securities International (Hong Kong) Limited, FUZE SECURITIES (INTERNATIONAL) LIMITED, Hafoo Securities Limited, Tiger Brokers (HK) Global Limited |
TIME TABLE
| Application Period | Aug 07 (Thu) - noon, Aug 12 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Aug 14 (Thu) |
| Result Announcement Date | On or before Aug 14 (Thu) |
| Result Announcement Date | On or before Aug 15 (Fri) |
| Dealings in Shares commence on | Aug 15, 2025. (Fri) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $18.68 |
| Capitalization (H Shares) | 7.85B |
| NAV / share ($) | $3.03 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 18.68, the net proceeds raised would be HKD 610.10M, of which |
| 90% : Clinical trials and planned commercial launch of Efsubaglutide Alfa of Core Product |
| 10% : Working capital |
IPO NEWS
| 15/08/2025 16:08 |
| {New Stock}INNOGEN-B(02591) ends up 206.48% at HK$57.25 |
| 15/08/2025 09:20 |
| {New Stock}INNOGEN-B(02591) opens up 285.44% at HK$72 |
| 14/08/2025 18:35 |
| {New Stock}INNOGEN-B ends up 274.73% at HK$70 on grey market |
| 14/08/2025 16:20 |
| {New Stock}INNOGEN-B up 275.54% at HK$70.15 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).